Expert Q&A on Patent Eligibility of Life Sciences Inventions
November 14, 2019
Practical Law Intellectual Property & Technology
Some experts have called the standards for determining patent eligibility under Section 101 of the Patent Act incoherent. This “incoherence” is particularly challenging for the life sciences industry where certain diagnostic inventions are now unpatentable. In this Q&A, Finnegan attorneys Charles Collins-Chase and Sara Leiman address patent subject matter eligibility, global patent strategies for protecting life sciences inventions, and other legal and regulatory mechanisms to protect life sciences inventions.
Downloadable Files
Related Practices
Related Industries
Related Professionals
- Charles T. Collins-Chase
- Partner
- Washington, D.C.
- +1 202 408 4108
- Sara A. Leiman, Ph.D.
- Associate
- Boston, MA
- +1 617 646 1651
Originally printed in Practical Law Intellectual Property & Technology on November 14, 2019. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.
